Drug intelligence / Profile preview

AT-1362

Development stage: Discontinued
Lead developer: JW C&C Research Lab
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

AT-1362 is a potent, selective, and competitive small molecule thrombin inhibitor originally developed by JW C&C Research Lab (C&C Research Laboratories) for the treatment of thrombotic diseases. It exhibits a Ki value of 6.7 nM against thrombin. In preclinical rat models of venous and arterial thrombosis, AT-1362 demonstrated significant antithrombotic efficacy and improved vessel patency without prolonging bleeding time. Development of the compound has been discontinued.

Other names: 4-(2-(2-(2-(6-amidino-1-ethylindol-2-yl)ethyl)pyrrolidinylcarbonyl)pyrrolidinyl)-2-amino-4-oxobutanoic acid

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on AT-1362.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-1362.